Home > Introducing Cris Constantinescu
Multiple Sclerosis

Introducing Cris Constantinescu

Published Online: October 25th 2016

We are pleased to introduce Cris Constantinescu as the new Editor in Chief for the European Neurological Review. In this interview Prof. Constantinescu discusses his research interests and his aims for the journal over the next year.

INTRODUCING THE NEW EUROPEAN NEUROLOGICAL REVIEW EDITOR-IN-CHIEF, CRIS CONSTANTINESCU

FILMED AT THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) ANNUAL MEETING, SEPTEMBER 2016

COULD YOU TELL US A LITTLE ABOUT YOURSELF AND YOUR CAREER TO DATE?

00:16 – So I’ve been in Nottingham, working as a neurologist for the last 17 years. Previously, I studied medicine at Boston University in the United States, and I did some training in neurology, in Philadelphia, at the University of Pennsylvania. That was my neurology residency, and then I did some fellowships in neuroimmunology and neurorehabilitation, also at Penn, and I ended up doing a PhD in immunology at Penn. After that, I worked for a while in the United States, and then I moved to Europe. I worked in Switzerland in the MS team for about two years. And then, as I said, about 17 years ago, I moved to Nottingham. In 2004, I became Professor and Head of the… Chair of the division of Clinical Neurology at Nottingham.

WHAT ARE YOUR MAIN RESEARCH INTERESTS?

01:30 – So my main research interest is in multiple sclerosis. I’ve been very interested in immunological aspects of MS; MS is an autoimmune disease. And I was looking at immunological mechanisms, in particular cytokine dysregulation in MS, so the balance between pro- and anti-inflammatory cytokines which seems to be dysregulated in MS; and also modalities of modulating the immune system to treat MS.

02:05 – And since the early days, that was a main aim of our research and now, of course, most of the drugs that we have for MS now are doing this; are aiming at modulating the immune system in a way in which the inflammation is reduced in the brain. So I think, in that respect, I worked from the preclinical models to phase 4 clinical trials in MS.

02:38 – And also, another interest of mine has been imaging in MS, so I have done some, and still do some work in terms of finding modalities to image the white matter and grey matter damage caused by the MS. And, in particular, as it relates to discovering subtle disease, on the one hand, and on the other hand, perhaps finding ways to use these imaging modalities as outcome measures in clinical trials, or for following the natural history of MS.

WHAT DO YOU CONSIDER THE GREATEST STRENGTHS OF EUROPEAN NEUROLOGICAL REVIEW AND WHAT ARE YOUR AIMS FOR THE JOURNAL OVER THE NEXT YEAR?

03:23 – In each issue, it has topics that cover neurology in general. I think it’s a unique source almost for writing about meetings, and what’s been discussed at meetings or satellite symposia of specific meetings, and I think that’s one of the strengths of the journal. The quality of the reviews is always very high, I think; that would be an important thing. Maybe diversifying the topics, perhaps finding some new topics. Not just therapeutics, but maybe some topics about diagnostic methods, some topics about various clinical aspects, or maybe new research in various neurological diseases. I think that would be great. And I hope that by doing that, the quality of the journal will increase and also perhaps the journal would be able to be included in PubMed, which would be a great advantage and a great incentive for people to submit papers to the journal.

Share this Video
Related Videos In Multiple Sclerosis
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72